Loading...

Alana Epstein

Title(s)Adjunct Lecturer, Dept. of Adult Mental Health and Wellness
SchoolSchool of Social Work
Phone+1 213 740 9448
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024. PMID: 29789628.
      View in: PubMed
    2. Kadin ME, Morgan J, Xu H, Epstein AL, Sieber D, Hubbard BA, Adams WP, Bacchi CE, Goes JCS, Clemens MW, Medeiros LJ, Miranda RN. IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis. Hum Pathol. 2018 Aug; 78:54-62. PMID: 29689246.
      View in: PubMed
    3. Zheng L, Hu P, Wolfe B, Gonsalves C, Ren L, Khawli LA, Kaslow HR, Epstein AL. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. Int J Mol Sci. 2017 Dec 20; 18(12). PMID: 29261129.
      View in: PubMed
    4. Alharshawi K, Marinelarena A, Kumar P, El-Sayed O, Bhattacharya P, Sun Z, Epstein AL, Maker AV, Prabhakar BS. PKC-? is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells. Sci Rep. 2017 Jul 26; 7(1):6594. PMID: 28747670.
      View in: PubMed
    5. Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, Kadin ME, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. Proc Natl Acad Sci U S A. 2017 04 11; 114(15):3975-3980. PMID: 28356514.
      View in: PubMed
    6. Kumar P, Alharshawi K, Bhattacharya P, Marinelarena A, Haddad C, Sun Z, Chiba S, Epstein AL, Prabhakar BS. Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling. Sci Rep. 2017 01 03; 7:39751. PMID: 28045060.
      View in: PubMed
    7. Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, Theil FP. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. J Immunol Res. 2016; 2016:2342187. PMID: 27579329.
      View in: PubMed
    8. Kadin ME, Deva A, Xu H, Morgan J, Khare P, MacLeod RA, Van Natta BW, Adams WP, Brody GS, Epstein AL. Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthet Surg J. 2016 Jul; 36(7):773-81. PMID: 26979456.
      View in: PubMed
    9. Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell TE, Li Z, Epstein AL. Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models. Cancer Immunol Immunother. 2016 May; 65(5):511-23. PMID: 26960932; PMCID: PMC4841721 [Available on 05/01/17].
    10. Andersen BM, Xia J, Epstein AL, Ohlfest JR, Chen W, Blazar BR, Pennell CA, Olin MR. Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant. J Immunother Cancer. 2016; 4:11. PMID: 26885373; PMCID: PMC4755027.
    11. Angell TE, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016 Mar; 26(3):381-9. PMID: 26756227; PMCID: PMC4790214 [Available on 03/01/17].
    12. Jang JK, Chretin J, Bruyette D, Hu P, Epstein AL. Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia®) in Dogs with Spontaneous Malignancies. J Cancer Sci Ther. 2015; 7(6):167-174. PMID: 26635918.
      View in: PubMed
    13. Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, Carlson G, Lechner MG, Epstein AL. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015 Mar; 135(3):695-705. PMID: 25490535.
      View in: PubMed
    14. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. PMID: 25294906; PMCID: PMC4252612.
    15. Bryan RA, Jiang Z, Jandl T, Strauss J, Koba W, Onyedika C, Morgenstern A, Bruchertseifer F, Epstein AL, Dadachova E. Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. Expert Rev Anticancer Ther. 2014 Oct; 14(10):1243-9. PMID: 25156106.
      View in: PubMed
    16. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93. PMID: 24955518; PMCID: PMC4148060.
    17. Aluri SR, Shi P, Gustafson JA, Wang W, Lin YA, Cui H, Liu S, Conti PS, Li Z, Hu P, Epstein AL, MacKay JA. A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody. ACS Nano. 2014 Mar 25; 8(3):2064-76. PMID: 24484356; PMCID: PMC4004287.
    18. Andoh T, Fujimoto T, Sudo T, Suzuki M, Sakurai Y, Sakuma T, Moritake H, Sugimoto T, Takeuchi T, Sonobe H, Epstein AL, Fukumori Y, Ono K, Ichikawa H. Boron neutron capture therapy as new treatment for clear cell sarcoma: trial on different animal model. Appl Radiat Isot. 2014 Jun; 88:59-63. PMID: 24389062.
      View in: PubMed
    19. Murphy KA, Erickson JR, Johnson CS, Seiler CE, Bedi J, Hu P, Pluhar GE, Epstein AL, Ohlfest JR. CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. J Immunol. 2014 Jan 01; 192(1):224-33. PMID: 24293627; PMCID: PMC4068509.
    20. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013 Nov-Dec; 36(9):477-89. PMID: 24145359; PMCID: PMC3910494.
    21. Jang JK, Khawli LA, Park R, Wu BW, Li Z, Canter D, Conti PS, Epstein AL. Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models. Mol Cancer Ther. 2013 Dec; 12(12):2827-36. PMID: 24130055; PMCID: PMC3929394.
    22. Ephrem A, Epstein AL, Stephens GL, Thornton AM, Glass D, Shevach EM. Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur J Immunol. 2013 Sep; 43(9):2421-9. PMID: 23722868.
      View in: PubMed
    23. Russell SM, Lechner MG, Mokashi A, Megiel C, Jang JK, Taylor CR, Looijenga LH, French CA, Epstein AL. Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1. Urology. 2013 Feb; 81(2):464.e1-9. PMID: 23374840; PMCID: PMC4179199.
    24. Li Z, Jang JK, Lechner MG, Hu P, Khawli L, Scannell CA, Epstein AL. Generation of tumor-targeted antibody-CpG conjugates. J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. PMID: 23279945.
      View in: PubMed
    25. Nadelson J, Epstein A. A rare case of noninsulinoma pancreatogenous hypoglycemia syndrome. Case Rep Gastrointest Med. 2012; 2012:164305. PMID: 23213581; PMCID: PMC3508526.
    26. Lechner MG, Megiel C, Church CH, Angell TE, Russell SM, Sevell RB, Jang JK, Brody GS, Epstein AL. Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma. Clin Cancer Res. 2012 Sep 01; 18(17):4549-59. PMID: 22791880.
      View in: PubMed
    27. Murphy KA, Lechner MG, Popescu FE, Bedi J, Decker SA, Hu P, Erickson JR, O'Sullivan MG, Swier L, Salazar AM, Olin MR, Epstein AL, Ohlfest JR. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin Cancer Res. 2012 Sep 01; 18(17):4657-68. PMID: 22781551; PMCID: PMC3432688.
    28. Epstein AL. Unique approach for B lymphoma therapy. Blood. 2012 Apr 19; 119(16):3647-8. PMID: 22517869.
      View in: PubMed
    29. Stathopoulos A, Pretto C, Devillers L, Pierre D, Hofman FM, Epstein AL, Farghadani H, Kruse CA, Jadus MR, Chen TC, Schijns VE. Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators. J Clin Cell Immunol. 2012; Suppl 5:004. PMID: 24955288.
      View in: PubMed
    30. Lechner MG, Russell SM, Bass RS, Epstein AL. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy. 2011 Nov; 3(11):1317-40. PMID: 22053884; PMCID: PMC3226699.
    31. Russell SM, Lechner MG, Gong L, Megiel C, Liebertz DJ, Masood R, Correa AJ, Han J, Puri RK, Sinha UK, Epstein AL. USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics. Oral Oncol. 2011 Sep; 47(9):810-7. PMID: 21719345; PMCID: PMC3164740.
    32. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, Epstein AL. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011 Jun 09; 9:90. PMID: 21658270; PMCID: PMC3128058.
    33. Lechner MG, Epstein AL. A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin Cancer Res. 2011 Apr 01; 17(7):1645-8. PMID: 21288925; PMCID: PMC4237605.
    34. Lechner MG, Lade S, Liebertz DJ, Prince HM, Brody GS, Webster HR, Epstein AL. Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer. 2011 Apr 01; 117(7):1478-89. PMID: 21425149; PMCID: PMC4175713.
    35. Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res. 2010 Nov 15; 70(22):9041-52. PMID: 21045144; PMCID: PMC3058673.
    36. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010 Aug 15; 185(4):2273-84. PMID: 20644162; PMCID: PMC2923483.
    37. Liebertz DJ, Lechner MG, Masood R, Sinha UK, Han J, Puri RK, Correa AJ, Epstein AL. Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol. 2010 Feb 22; 2:5. PMID: 20175927; PMCID: PMC2841166.
    38. Phares TW, Ramakrishna C, Parra GI, Epstein A, Chen L, Atkinson R, Stohlman SA, Bergmann CC. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J Immunol. 2009 May 01; 182(9):5430-8. PMID: 19380790; PMCID: PMC2909606.
    39. Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P, Epstein AL. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother. 2008 Apr; 31(3):235-45. PMID: 18317364.
      View in: PubMed
    40. Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H, Lutsiak ME, Khawli LA, Epstein AL. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res. 2008 Jan 15; 14(2):579-88. PMID: 18223234.
      View in: PubMed
    41. Wang H, Cao C, Li B, Chen S, Yin J, Shi J, Ye D, Tao Q, Hu P, Epstein A, Ju D. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. Cancer Immunol Immunother. 2008 May; 57(5):677-84. PMID: 17934732.
      View in: PubMed
    42. Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P, Epstein AL. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res. 2007 Jul 01; 13(13):4016-25. PMID: 17606736.
      View in: PubMed
    43. Zhang N, Khawli LA, Hu P, Epstein AL. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. PMID: 17651040.
      View in: PubMed
    44. Arias RS, Flanagan ML, Miller KD, Nien YC, Hu P, Gray D, Khawli LA, Epstein AL. RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. PMID: 17600493.
      View in: PubMed
    45. Tobin E, Denardo G, Zhang N, Epstein AL, Liu C, Denardo S. Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. Leuk Lymphoma. 2007 May; 48(5):944-56. PMID: 17487739.
      View in: PubMed
    46. Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P, Epstein AL. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res. 2007 May 01; 13(9):2758-67. PMID: 17460060.
      View in: PubMed
    47. Flanagan ML, Arias RS, Hu P, Khawli LA, Epstein AL. Soluble Fc fusion proteins for biomedical research. Methods Mol Biol. 2007; 378:33-52. PMID: 18605076.
      View in: PubMed
    48. Liu A, Hu P, Khawli LA, Epstein AL. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. PMID: 16799338.
      View in: PubMed
    49. Flanagan ML, Khawli LA, Hu P, Epstein AL. H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models. J Immunother. 2006 May-Jun; 29(3):274-83. PMID: 16699370.
      View in: PubMed
    50. Yu L, Ju DW, Chen W, Li T, Xu Z, Jiang C, Chen S, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm. 2006 Feb; 21(1):5-14. PMID: 16480326.
      View in: PubMed
    51. Liu A, Hu P, Khawli LA, Epstein AL. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res. 2005 Dec 01; 11(23):8492-502. PMID: 16322313.
      View in: PubMed
    52. Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. PMID: 16115941.
      View in: PubMed
    53. Khawli LA, Hu P, Epstein AL. NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. PMID: 15837764.
      View in: PubMed
    54. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol. 2005 Mar 01; 23(7):1538-47. PMID: 15735129.
      View in: PubMed
    55. Li J, Hu P, Khawli LA, Yun A, Epstein AL. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics. 2004 Feb; 23(1):1-10. PMID: 15000842.
      View in: PubMed
    56. Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res. 2003 Dec 01; 63(23):8384-92. PMID: 14679000.
      View in: PubMed
    57. Khawli LA, Alauddin MM, Hu P, Epstein AL. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. PMID: 14969605.
      View in: PubMed
    58. Ottonello L, Epstein AL, Mancini M, Dapino P, Dallegri F. Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G. J Leukoc Biol. 2004 Jan; 75(1):99-105. PMID: 14525961.
      View in: PubMed
    59. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003 Aug 15; 63(16):5046-53. PMID: 12941833.
      View in: PubMed
    60. Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics. 2003 Aug; 22(4):197-207. PMID: 14511565.
      View in: PubMed
    61. Li J, Hu P, Khawli LA, Epstein AL. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother. 2003 Jul-Aug; 26(4):320-31. PMID: 12843794.
      View in: PubMed
    62. Biela BH, Khawli LA, Hu P, Epstein AL. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. PMID: 12954121.
      View in: PubMed
    63. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003 May 21; 95(10):741-9. PMID: 12759392.
      View in: PubMed
    64. Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood. 2003 Jun 15; 101(12):4853-61. PMID: 12609842.
      View in: PubMed
    65. Khawli LA, Biela B, Hu P, Epstein AL. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid Hybridomics. 2003 Feb; 22(1):1-9. PMID: 12713684.
      View in: PubMed
    66. Sharifi J, Khawli LA, Hu P, Li J, Epstein AL. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics. 2002 Dec; 21(6):421-32. PMID: 12573106.
      View in: PubMed
    67. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm. 2002 Aug; 17(4):359-70. PMID: 12396700.
      View in: PubMed
    68. Moritake H, Sugimoto T, Asada Y, Yoshida MA, Maehara Y, Epstein AL, Kuroda H. Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. Cancer Genet Cytogenet. 2002 May; 135(1):48-56. PMID: 12072203.
      View in: PubMed
    69. Khawli LA, Biela BH, Hu P, Epstein AL. Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells. Hybrid Hybridomics. 2002 Feb; 21(1):11-8. PMID: 11991812.
      View in: PubMed